Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing novel therapeutics for autoimmune diseases and cancer, today announced that it will present at the 11 th Annual Needham Healthcare Conference on Wednesday, April 4th 2012, at 4:00 pm EST at the New York Palace Hotel in New York City, NY. A live audio webcast of the presentation will be available in the Investor section of Idera's website: www.iderapharma.com. An archived version will also be available on the Company's website after the event for a limited time. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has clinical development programs in autoimmune and inflammatory diseases and cancer. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants. The Company is also advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.